OVERVIEW

Key Insights: Lymphoma and Myeloma 2018 - A Focus on Lymphoma is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
CME:
NACCME designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™.

Physican Assistants:

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.50 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 credit(s).

CNE
This continuing nursing education activity awards 0.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.50 contact hours.

CPE
This knowledge-based activity (JA0006201-9999-18-209-H01-P) is approved for 0.50 contact hours (0.005 CEUs) of continuing pharmacy education.

Course Overview:
Clinicians who treat hematologic malignancies in 2018 have more insight into the inner molecular mechanisms of leukemias, lymphoma, and myeloma and have more treatment options than at any previous time in medical history. Today’s hematologists/oncologists, physician assistants, nurse practitioners, and other healthcare professionals who manage patients with hematologic malignancies must keep pace with a disconcertingly massive deluge of information on both nascent and established treatment options such as chemotherapies, targeted therapies, and immunotherapies in different sequences and combinations, as well as nonpharmacologic approaches. The intricacies of treatment are further compounded by patient variables such as whether the disease is newly diagnosed or relapsed/refractory and if the patient is generally fit and healthy or frail and fragile.

This activity intended to extend the reach of the content presented during L&M 2018 to clinicians who were unable to participate in the live congress, and to reinforce key points discussed in therapy area of lymphoma.

Course Objectives:
• Assess the prognostic impact of molecular biomarkers and genetic mutations that are common to hematologic malignancies
• Evaluate the emerging role of immunotherapies as an intervention for hematologic malignancies
• Devise tailored therapeutic strategies designed to realize optimal therapeutic response from hematologic cancer patients
• Describe the mechanisms of action of new or emerging treatments that are designed to target molecular biomarkers or genetic aberrations that are frequently observed in hematologic cancers

Additional details will be posted as soon as they are available.